Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer
- 20 August 2014
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (11) , 11613-11620
Abstract
The purpose of the present study is to explore the relation between glycolytic metabolism assessed by 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) and final neoadjuvant chemotherapy (NC) response in locally advanced breast tumors. Of women with breast cancer, 126 were prospectively evaluated. All patients underwent 18F-FDG PET/CT previous to NC. Standard uptake value (SUV) max was calculated in the primary tumor. After NC, residual primary tumor specimen was histopathologically classified according to Miller and Payne tumor regression grades (TRG), from G1 to G5 and in response groups as good responders (G4 or G5), partial responders (G2 or G3), and non-responders (G1). Furthermore, residual lesions were classified following a binary assessment as responders (G4 or G5) and non-responders (the rest of cases). The relationship between SUV max with TRG and response groups was evaluated. Of tumors, 127 were assessed (a patient had bilateral breast lesions). TRG were as follows: G1 (27), G2 (27), G3 (32), G4 (11), and G5 (30). Forty-one were classified as good responders, 59 as partial responders, and 27 as non-responders. For the binary assessment, 41 lesions were classified as responders and 86 as non-responders. We found statistical differences (p = 0.02) between the mean SUV max and TRG with greater SUV values for G5 compared to the other TRG. Good responders showed greater mean SUV max ± SD compared to partial responders and non-responders (10.51 ± 6.64 for good responders, 6.94 ± 5.81 for partial responders, and 5.23 ± 2.76 for non-responders; p = 0.001). Baseline tumor metabolism assessing by FDG PET/CT was associated with the final histopathologic status after neoadjuvant chemotherapy, with greater SUV max values for good responders compared to the less responder cancers.Keywords
This publication has 28 references indexed in Scilit:
- 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancerRevista Española de Medicina Nuclear e Imagen Molecular, 2012
- FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial resultsActa Radiologica, 2012
- Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first courseBreast Cancer Research and Treatment, 2011
- 18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete responseInternational Journal of Clinical Oncology, 2011
- Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-AnalysisJournal of Nuclear Medicine, 2010
- [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Monitoring primary breast cancer throughout chemotherapy using FDG-PETBreast Cancer Research and Treatment, 2006
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002